Association of wheatgrass (Triticum aestivum) preparation in regulation of antigen presentation through the immunomodulation and epigenetic modification in acute leukemia.

Authors

Anuraag Dasgupta, Bandi Moneesha Reddy, Sarnabi Banerjee, Merina Roy, Anushka Kumar, Oishi Mukherjee, Roshni Bibi, R Pradeep, Melvin George, Saptak Banerjee, Koustav Sarkar

Published in

3 Biotech. Volume 16. Issue 8. Pages 308. Epub Jul 04, 2026.

Abstract

Acute Leukemia is a haematological cancer accounting for around 25% and 80% of both patient populations. Some immunotherapeutic strategies that are non-toxic plant-based products should be discovered. The current strategies used to reduce cancer cells in the body, such as cancer chemotherapy, radiation therapy, and surgical procedures, exhibit adverse effects. We used the wheatgrass preparation to immunomodulate ALL and AML because we know that Triticum aestivum has many anti-cancer capabilities. According to mRNA expression, WGP inhibits the activities of T_H17, T_H2 & T regulatory cytokines (IL-17, IL-10, and IL-4), a pro-tumorigenesis factor (c-MYC), and an angiogenesis factor (VEGFA). The ELISA analysis WGP upregulates the extracellular levels of IL12, TNFα, and IFNγ. Analysis by chromatin immunoprecipitation reveals the activities of transcription factors, activating histone markers (H₃K₄Me₃, H₃K₁₄Ac), and tumour suppressors (p53) following WGP treatment. The data of RDIP analysis of WGP treatment reduced the frequency of R-loop formation at the IFNγ and TBX21 gene loci. Wheat Grass Preparation treatment increased the activity of CD8 + CTL cells as per FACS, while it encourages cytotoxicity of ALL and AML to Jurkat and HL60, while m⁶A RNA Methylation showed that WGP treatment signifies the absolute and relative quantification, which triggers the tumor protective immunity. It increased the percentage of methylation of the HDAC1 gene and reduced in the p53 gene in CpG islands, according to data on DNA methylation. As per our results, WGP also plays an important role in epigenetic mechanisms and modifications in ALL and AML patients.
The online version contains supplementary material available at 10.1007/s13205-026-04949-y.

PMID:
42404977
Bibliographic data and abstract were imported from PubMed on 06 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.